FIELD: bioengineering.
SUBSTANCE: invention proposes a monoclonal antibody and its antigen-bonding fragment that can specifically bond with a human IL-17A and are described by CDR sequences. Besides, it discloses a DNA, encoding the antibody or its antigen-bonding fragment; an expression vector; a cellular line and the production of the antibody or its fragment. Also, it proposes a pharmaceutical composition and the method of treatment a mediated IL-17A disease or dysfunction.
EFFECT: stable blocking of IL-17A under thermal stress conditions, increased period of semi-ejection from blood.
27 cl, 16 dwg, 1 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH AFFINITY AND AGGREGATIONALLY STABLE ANTIBODIES BASED ON VL VARIABLE DOMAINS AND VHH DERIVATIVE | 2014 |
|
RU2609627C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2019 |
|
RU2754760C2 |
| ANTIBODY OR ITS ANTI-BINDING FRAGMENT, WHICH IS CAPABLE TO BE BOUND USING THE INTERLEUKIN-6 HUMAN RECEPTOR | 2016 |
|
RU2656160C2 |
| MONOCLONAL ANTIBODIES AGAINST IL-21 OF HUMAN BEING | 2008 |
|
RU2504552C2 |
| COMBINED THERAPY WITH USING ALPHA5BETA1 ANTAGONISTS | 2007 |
|
RU2465282C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
| OCTAHYDROPENTALENE COMPOUNDS AS CHEMOKINE RECEPTOR ANTAGONISTS | 2008 |
|
RU2481332C2 |
| IMMUNOGLOBULIN WITH DOUBLE VARIABLE DOMAINS AND ITS APPLICATIONS | 2006 |
|
RU2515108C2 |
| HETERODIMERIC POLIPEPTIDES IL-17 A/F AND POSSIBILITIES OF THEIR THERAPEUTIC APPLICATION | 2007 |
|
RU2440134C2 |
